ArticleNagoya journal of medical science2026
A challenging case of giant atypical fibroxanthoma on non-chronically sun-damaged skin: a case report with TP53 somatic mutation (c.375+1 G>A).
Article in Nagoya journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical fibroxanthoma (AFX) is a rare tumor of uncertain histogenetic origin, generally seen in elderly patients' chronically sun-damaged skin, most frequently in the head and neck region. Due to the absence of specific histopathologic features, AFX is a diagnosis of exclusion. Herein, we report clinical, histopathological, and molecular features of a young patient with a recurrent and giant AFX lesion on non-chronically sun-damaged skin. Histologically, the tumor was well-circumscribed, encapsulated, and dermal-based, composed of highly atypical and pleomorphic bizarre spindled cells with hyperchromatic and irregular nuclei and scarce multinucleated giant cells. There was no subcutaneous invasion, necrosis, or perineural/perivascular invasion. Tumoral cells were diffusely and strongly positive for CD10 but negative for melanocytic, cytokeratin, and muscle immunohistochemical markers. Almost five years after the excision, no recurrence and/or distant metastasis was observed. A pathogenic variant of a TP53 somatic mutation (c.375+1 G>A) was identified in the tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.